All Pathways
NeurosurgeryManagement

Chronic Subdural Hematoma - Surgical Management (SVIN 2025)

Chronic Subdural Hematoma - Surgical Management (SVIN 2025): Chronic Subdural Hematoma (cSDH) Identified → Symptomatic? → Symptomatic - Evaluate for Sur...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Chronic Subdural Hematoma (cSDH) Identified

    CT showing chronic (hypodense/isodense) extra-axial collection

    1. Decision

      Symptomatic?

      Assess for symptoms requiring intervention

      • Headache
      • Cognitive decline/confusion
      • Gait disturbance
      • Focal weakness
      • Speech difficulty
      • Seizures
      1. Action

        Symptomatic - Evaluate for Surgery

        Most symptomatic patients benefit from surgery

        1. Decision

          On Anticoagulation/Antiplatelets?

          Common in elderly cSDH population

          1. Action

            Anticoagulation Management

            Hold/reverse prior to surgery

            • Hold warfarin, give Vitamin K ± PCC
            • Hold DOACs (half-life dependent)
            • Hold aspirin: controversial, often continued
            • Dual antiplatelet: hold P2Y12 if possible
            • Platelet transfusion rarely needed
            1. Decision

              Surgical Approach

              Select based on hematoma characteristics

              1. Action

                Burr Hole Drainage

                Most common approach (SVIN 2025 consensus)

                • 1-2 burr holes over collection
                • Irrigate until clear
                • Place subdural drain (24-48h)
                • Drain reduces recurrence
                • Similar outcomes to craniotomy
                1. Decision

                  Consider MMA Embolization?

                  Middle meningeal artery embolization per SVIN 2025 Consensus

                  • EMBOLISE: 4.1% vs 11.3% recurrence (p=0.008)
                  • STEM: 16% vs 36% recurrence (OR 0.36)
                  • MAGIC-MT: 6.7% vs 9.9% recurrence
                  • Can be done with or after surgery
                  • Especially for high recurrence risk
                  1. Action

                    MMA Embolization (SVIN 2025)

                    Reduces recurrence by ~50% per RCT data (Class I evidence)

                    • Onyx, Squid, or n-BCA embolic agents
                    • Can be done at time of surgery or after
                    • Fewer serious adverse events vs surgery alone
                    • SVIN: 'may become standard of care'
                    • EMPROTECT 2025: confirms benefit in high-risk
                    1. Action

                      Post-Operative Care

                      Standard post-craniotomy management

                      • Subdural drain for 24-48h
                      • Flat positioning (controversial)
                      • Hydration to promote brain re-expansion
                      • Repeat CT before discharge
                      • Seizure prophylaxis (institution-dependent)
                      1. Decision

                        Recurrence?

                        Recurrence rate 5-30%

                        1. Action

                          Recurrence Management

                          Options for recurrent cSDH

                          • Repeat burr hole drainage
                          • MMA embolization (if not done)
                          • Craniotomy with membrane removal
                          • Address underlying factors (anticoag, atrophy)
                        2. Outcome

                          Resolution

                          Follow-up imaging to confirm resolution; resume anticoagulation per indication

              2. Action

                Craniotomy

                Consider for organized/septated hematoma

                • Better for loculated collections
                • Allows membrane removal
                • Higher morbidity than burr hole
                • Reserved for complex cases
              3. Action

                Twist Drill Craniostomy

                Bedside option for poor surgical candidates

                • Can be done at bedside
                • Lower anesthesia risk
                • Higher recurrence rate
                • For patients unfit for OR
      2. Action

        Asymptomatic/Minimal Symptoms

        Consider observation for small, asymptomatic cSDH

        • Serial imaging q2-4 weeks
        • Monitor for symptom development
        • Many resolve spontaneously
        • Address anticoagulation if applicable

Guideline Source

SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025)

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Anticoagulation resumption timing remains controversial
  • MMA embolization not available at all centers
  • Optimal drain duration not standardized
  • Bilateral cSDH may require staged approach
  • Does not address pediatric populations

Contraindicated Populations

pediatric

Applicable Regions

USEUGlobal

EU: Similar surgical approaches, local variation in MMA availability

US: MMA embolization increasingly available

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Chronic Subdural Hematoma - Surgical Management (SVIN 2025)?

The Chronic Subdural Hematoma - Surgical Management (SVIN 2025) is a management clinical algorithm for Neurosurgery. It provides a structured decision tree to guide clinical decision-making, based on SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025).

What guideline is the Chronic Subdural Hematoma - Surgical Management (SVIN 2025) based on?

This algorithm is based on SVIN Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment (2025) (DOI: 10.1161/SVIN.125.001814).

What are the limitations of the Chronic Subdural Hematoma - Surgical Management (SVIN 2025)?

Known limitations include: Anticoagulation resumption timing remains controversial; MMA embolization not available at all centers; Optimal drain duration not standardized; Bilateral cSDH may require staged approach; Does not address pediatric populations. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Chronic Subdural Hematoma - Surgical Management (SVIN 2025) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free